Clinical trial end points: On the road to nowhere?

Neurology

Volumn 58, Issue 5, 2002, Pages 679-686

  Holloway, Robert G ^a   Dick, Andrew W ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; OUTCOMES RESEARCH; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

EID: 0037066097     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.5.679     Document Type: Review

References (57)

1. Guidelines for carotid endarterectomy: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
2. Practice parameter: Stroke prevention in patients with nonvalvular atrial fibrillation
3. Effect of deprenyl on the progression of disability in early Parkinson's disease
4. Selegiline delays the onset of disability in de novo parkinsonian patients
5. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial
6. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole of levodopa
7. Dopamine agonists in early therapy for Parkinson disease
8. An algorithm (decision tree) for the management of Parkinson's disease 2001: Treatment guidelines
9. A regulatory authority's opinion about surrogate endpoints
10. Understanding clinical trials: Intermediate markers as surrogate endpoints in cancer research
11. Perspective: Validating surrogate markers - Are we being naive?
12. Surrogate endpoints in clinical trials: Cardiovascular diseases
13. What are surrogate outcome measures and why do they fail in clinical research?
14. Surrogate endpoints in clinical trials: Ophthalmologic disorders
15. Multiple sclerosis: Use of MRI in evaluating new therapies
16. Preliminary analysis of the Concorde trial
17. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
18. Interpreting precursor studies: What polyp trials tell us about largebowel cancer
19. Guidance for industry. Fast track drug development programsdesignation, development, and application review
20. Criteria for the validation of surrogate endpoints in randomized experiments
21. Surrogate endpoints in clinical trials: Definitions and operational criteria
22. Estimating the proportion of treatment effect explained by a surrogate marker
23. Statistical validation of intermediate endpoints for chronic diseases
24. Surrogate end points in clinical trials: Are we being misled?
25. Focusing technology assessment using medical decision theory
26. An approach to the validation of markers for use in AIDS clinical trials
27. Beware of surrogate outcome measures
28. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
29. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
30. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction
31. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine
32. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
33. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
34. Glucose tolerance and mortality, including a substudy of tolbutamide treatment
35. The association between betaagonist use and death from asthma: A meta-analytic integration of case-control studies
36. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: A critical analysis based on 100 studies
37. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
38. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-dopa
39. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
40. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial
41. Immediate-release, controlled-release carbidopa/levodopa in PD, a 5-year randomized multicenter study
42. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease
43. Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
44. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study
45. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
46. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations
47. Imaging. Molecular map for neurode-generation
48. Safety and efficacy of pramipexole in early Parkinson disease: A randomized dose-ranging study
49. Datatop: A decade of neuroprotective inquiry
50. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease
51. Outcomes research: Measuring the end results of health care
52. Getting oriented to patient-oriented outcomes
53. Identifying and valuing outcomes
54. The use of QALYs in health care decision making
55. Consideration in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institute of Health workshop
56. Are all significant P values created equal? The analogy between diagnostic tests and clinical research
57. Separating continuing medical education from pharmaceutical marketing